VolitionRx's Nu.Q NETs Assay Selected for French National Sepsis Detection Initiative

VolitionRx Ltd. announced that its Nu.Q NETs H3.1 assay has been selected as the exclusive biomarker for DETECSEPS, a French government-funded evaluation of early sepsis detection under the France 2030 plan. The program, led by the IHU SEPSIS and supported by a €6.3 million grant, aims to transform emergency care for patients with infection and risk of sepsis progression.

Professor Djillali Annane, Scientific Director of DETECSEPS, noted that combining Volition's Nu.Q H3.1 biomarker with a clinical score could improve early identification of sepsis and make a significant difference in emergency settings. He emphasized that H3.1 is highly correlated with disease severity and provides excellent prognostic utility for outcomes such as organ failure and mortality. The biomarker's prognostic power at ICU admission significantly exceeded established severity scores including APACHE II and SOFA.

Dr. Andrew Retter, Volition's Chief Medical Officer, stated that the company's biomarker can deliver results within one hour on the Immunodiagnostic Systems i10 automated analyzer, potentially enhancing emergency decision-making. Volition believes that through earlier identification of sepsis, lives can be saved, the quality of life of survivors can be improved, and the burden on healthcare systems can be reduced.

The selection of Volition's technology for this national initiative represents a significant validation of the company's epigenetic approach to disease detection. Sepsis, a life-threatening condition caused by the body's extreme response to infection, requires rapid diagnosis for effective treatment. Current diagnostic methods often lack the speed and accuracy needed in emergency situations, leading to delayed treatment and poorer outcomes.

The DETECSEPS program's focus on early detection aligns with growing recognition in the medical community that timely intervention is crucial for sepsis management. By providing results within one hour, Volition's technology could enable healthcare providers to make faster treatment decisions, potentially reducing mortality rates and improving patient recovery. The company is providing the Nu.Q H3.1 Assay pro-bono to enable this important evaluation.

This development has implications beyond France's healthcare system, as successful implementation could establish a new standard for sepsis detection globally. The integration of epigenetic biomarkers with clinical assessment tools represents an emerging trend in precision medicine, where multiple data points combine to improve diagnostic accuracy. For more information about Volition's technology, visit https://www.Volition.com.

The selection of Volition's assay for this government-funded initiative demonstrates growing confidence in epigenetic approaches to disease detection. As healthcare systems worldwide seek more efficient and accurate diagnostic tools, technologies that can provide rapid results while maintaining high prognostic accuracy are increasingly valuable. The DETECSEPS program's outcomes could influence sepsis detection protocols internationally, potentially leading to broader adoption of similar biomarker-based approaches in emergency medicine.